Want to join the conversation?
$OREX 2Q15 Q&A: Matteis of Leerink asked about updated planning with Takeda on potential diabetes study or investing in other promotional efforts. Mike answered that one is to follow lifecycle promotional commitments, how exactly company will allocate committed resources over time. Wants to focus resource allocation on what can drive most value.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.